These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28331953)

  • 1. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.
    Torosyan N; Mason K; Dahlbom M; Silverman DHS;
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1355-1363. PubMed ID: 28331953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
    Landau SM; Harvey D; Madison CM; Koeppe RA; Reiman EM; Foster NL; Weiner MW; Jagust WJ;
    Neurobiol Aging; 2011 Jul; 32(7):1207-18. PubMed ID: 19660834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET.
    Shokouhi S; Claassen D; Kang H; Ding Z; Rogers B; Mishra A; Riddle WR;
    J Nucl Med; 2013 Sep; 54(9):1564-9. PubMed ID: 23864720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
    Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
    BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
    Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW;
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia.
    Huang SH; Hsiao WC; Chang HI; Ma MC; Hsu SW; Lee CC; Chen HJ; Lin CH; Huang CW; Chang CC
    BMC Med Imaging; 2024 Mar; 24(1):75. PubMed ID: 38549082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment.
    Chételat G; Eustache F; Viader F; De La Sayette V; Pélerin A; Mézenge F; Hannequin D; Dupuy B; Baron JC; Desgranges B
    Neurocase; 2005 Feb; 11(1):14-25. PubMed ID: 15804920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.
    Herholz K; Westwood S; Haense C; Dunn G
    J Nucl Med; 2011 Aug; 52(8):1218-26. PubMed ID: 21764801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early identification of MCI converting to AD: a FDG PET study.
    Pagani M; Nobili F; Morbelli S; Arnaldi D; Giuliani A; Öberg J; Girtler N; Brugnolo A; Picco A; Bauckneht M; Piva R; Chincarini A; Sambuceti G; Jonsson C; De Carli F
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2042-2052. PubMed ID: 28664464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer's disease.
    Förster S; Buschert VC; Teipel SJ; Friese U; Buchholz HG; Drzezga A; Hampel H; Bartenstein P; Buerger K
    J Alzheimers Dis; 2011; 26 Suppl 3():337-48. PubMed ID: 21971473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
    Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
    Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.